Skip to main content

Articles

Page 1 of 7

  1. Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell lung cancer (NSCLC) patients. Howe...

    Authors: Mengke Niu, Ming Yi, Ning Li, Suxia Luo and Kongming Wu

    Citation: Experimental Hematology & Oncology 2021 10:18

    Content type: Review

    Published on:

  2. Hepatocellular carcinoma (HCC) is one of the common cancers that are very aggressive. The secreted cytokine transforming growth factor-β (TGF-β) promotes cancer metastasis by multiple mechanisms such as epithe...

    Authors: Shu Yang, Hongying Zhang, Hua Yang, Jin Zhang, Jiao Wang, Ting Luo, Yangfu Jiang and Hui Hua

    Citation: Experimental Hematology & Oncology 2021 10:17

    Content type: Research

    Published on:

  3. Cytokine release syndrome (CRS) is the most common toxicity induced by chimeric antigen receptor (CAR) T cell therapy. At present, anti-IL-6 agents including tocilizumab and siltuximab have been applied in the...

    Authors: Lina Zhang, Shuai Wang, Ji Xu, Run Zhang, Han Zhu, Yujie Wu, Liying Zhu, Jianyong Li and Lijuan Chen

    Citation: Experimental Hematology & Oncology 2021 10:16

    Content type: Letter to the Editor

    Published on:

  4. Belinostat is a histone deacetylase inhibitor approved for relapsed refractory peripheral T-cell lymphoma (PTCL). The primary objective of this study was to determine the maximum tolerated dose (MTD) of belino...

    Authors: Patrick B. Johnston, Amanda F. Cashen, Petros G. Nikolinakos, Anne W. Beaven, Stefan Klaus Barta, Gajanan Bhat, Steven J. Hasal, Sven De Vos, Yasuhiro Oki, Changchun Deng and Francine M. Foss

    Citation: Experimental Hematology & Oncology 2021 10:15

    Content type: Research

    Published on:

  5. The aim of the present study was to evaluate the circulating T regulatory cells (Tregs) in patients undergoing extracorporeal photopheresis (ECP) for the prevention of chronic graft-versus-host disease (GvHD) ...

    Authors: Crocchiolo Roberto, Cesana Clara, Girgenti Debora, Bertani Giambattista, Barba Claudia, Liga Giuseppa, Ferri Ursula, Crucitti Lara, Grillo Giovanni, Rossini Silvano and Cairoli Roberto

    Citation: Experimental Hematology & Oncology 2021 10:14

    Content type: Letter to the Editor

    Published on:

  6. Cancer stem cells (CSCs) are a small group of cancer cells, which contribute to tumorigenesis and cancer progression. Cancer cells undergoing epithelial-to-mesenchymal transition (EMT) acquire the chemoresista...

    Authors: Bing Dong, Shiyu Li, Shuangli Zhu, Ming Yi, Suxia Luo and Kongming Wu

    Citation: Experimental Hematology & Oncology 2021 10:12

    Content type: Review

    Published on:

  7. Hematologic malignancies (HMs) are a heterogeneous group of cancers that comprise diverse subgroups of neoplasms. So far, despite the major epidemiologic concerns about the quality of care, limited data are av...

    Authors: Mohammad Keykhaei, Masood Masinaei, Esmaeil Mohammadi, Sina Azadnajafabad, Negar Rezaei, Sahar Saeedi Moghaddam, Nazila Rezaei, Maryam Nasserinejad, Mohsen Abbasi-Kangevari, Mohammad-Reza Malekpour, Seyyed-Hadi Ghamari, Rosa Haghshenas, Kamyar Koliji, Farzad Kompani and Farshad Farzadfar

    Citation: Experimental Hematology & Oncology 2021 10:11

    Content type: Research

    Published on:

  8. Arsenic trioxide [ATO, inorganic arsenite (iAsIII) in solution] plays an important role in the treatment of acute promyelocytic leukemia (APL). However, the long-term adverse effects (AEs) and the retention of ar...

    Authors: Yu Zheng, Yuan-Fei Mao, Hui-Jin Zhao, Li Chen, Li-Ning Wang, Yun-Xiang Zhang, Jiong Hu, Jun-Min Li, Xiao-Yang Li and Hong-Ming Zhu

    Citation: Experimental Hematology & Oncology 2021 10:10

    Content type: Research

    Published on:

  9. Acute myeloid leukemia (AML) with the t(8;21)(q22;q22) chromosomal translocation is among the most common subtypes of AML and produces the AML1-ETO (RUNX1-ETO, RUNX1-RUNX1T1) oncogenic fusion gene. AML1-ETO funct...

    Authors: Daniel T. Johnson, Amanda G. Davis, Jie-Hua Zhou, Edward D. Ball and Dong-Er Zhang

    Citation: Experimental Hematology & Oncology 2021 10:8

    Content type: Research

    Published on:

  10. Fms-related tyrosine kinase 3 (FLT3) receptor serves as a prognostic marker and therapeutic target in acute myeloid leukemia (AML). Approximately one-third of AML patients carry mutation in FLT3, associated wi...

    Authors: Emma Rörby, Jörgen Adolfsson, Erik Hultin, Thomas Gustafsson, Kourosh Lotfi, Jörg Cammenga and Jan-Ingvar Jönsson

    Citation: Experimental Hematology & Oncology 2021 10:7

    Content type: Research

    Published on:

  11. Coronavirus disease 2019 (COVID-19) is associated with coagulation abnormalities which are indicators of higher mortality especially in severe cases.

    Authors: Runhui Zheng, Jing Zhou, Bin Song, Xia Zheng, Ming Zhong, Li Jiang, Chun Pan, Wei Zhang, Jiaan Xia, Nanshan Chen, Wenjuan Wu, Dingyu Zhang, Yin Xi, Zhimin Lin, Ying Pan, Xiaoqing Liu…

    Citation: Experimental Hematology & Oncology 2021 10:6

    Content type: Research

    Published on:

  12. Coronavirus disease 2019 (COVID-19) is a novel infectious viral disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two consecutively negative SARS-CoV-2 viral RNA test ( interv...

    Authors: Changqian Bao, Xiandong Tao, Wei Cui, Yuanyuan Hao, Shuaike Zheng, Bin Yi, Tiewen Pan, Ken H. Young and Wenbin Qian

    Citation: Experimental Hematology & Oncology 2021 10:5

    Content type: Letter to the Editor

    Published on:

  13. Classical Hodgkin lymphoma (cHL) and anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma (ALK+ ALCL) are B and T cell lymphomas respectively, which express the tumour necrosis factor receptor s...

    Authors: Zuoqiao Wu, Mary Nicoll and Robert J. Ingham

    Citation: Experimental Hematology & Oncology 2021 10:4

    Content type: Review

    Published on:

  14. Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of plasma cells in the bone marrow. To date, this disease is still incurable and novel therapeutic approaches are requi...

    Authors: Samah Elsaadi, Ida Steiro, Pegah Abdollahi, Esten N. Vandsemb, Rui Yang, Tobias S. Slørdahl, Torstein Baade Rø, Eline Menu, Anne-Marit Sponaas and Magne Børset

    Citation: Experimental Hematology & Oncology 2021 10:3

    Content type: Research

    Published on:

  15. The development of programmed cell death-1 inhibitor (PD-1) has shed light on the treatment of tumors with deficiencies in DNA mismatch repair system or microsatellite instability (dMMR/MSI). However, predicti...

    Authors: Qiao-Xuan Wang, Chun-Hua Qu, Yuan-Hong Gao, Pei-Rong Ding, Jing-Ping Yun, Dan Xie and Mu-Yan Cai

    Citation: Experimental Hematology & Oncology 2021 10:2

    Content type: Letter to the Editor

    Published on:

  16. Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1...

    Authors: Sakshi Jasra, Mohammed Kazemi, Nishi Shah, Jiahao Chen, Karen Fehn, Yanhua Wang, Ioannis Mantzaris, Noah Kornblum, Alejandro Sica, LizaMarie Bachier, Mendel Goldfinger, Kira Gritsman, Ira Braunschweig, Ulrich Steidl, Aditi Shastri and Amit Verma

    Citation: Experimental Hematology & Oncology 2021 10:1

    Content type: Letter to the Editor

    Published on:

  17. Authors: Ana Muntañola, Guillermo Villacampa, José Ángel Hernández-Rivas, Rosalía Alonso, Fátima Mirás, Santiago Osorio, Mónica Baile, Patricia Baltasar, Javier López Jiménez, Ines Hernandez-Rodriguez, Susana Valenciano, Ana Alfayate, Eva Gimeno, Abelardo Bárez, Ana C. Oliveira, Rosalía Riaza…

    Citation: Experimental Hematology & Oncology 2020 9:37

    Content type: Letter to the Editor

    Published on:

  18. CD44, a complex transmembrane glycoprotein, exists in multiple molecular forms, including the standard isoform CD44s and CD44 variant isoforms. CD44 participates in multiple physiological processes, and aberra...

    Authors: Hanxiao Xu, Mengke Niu, Xun Yuan, Kongming Wu and Aiguo Liu

    Citation: Experimental Hematology & Oncology 2020 9:36

    Content type: Review

    Published on:

  19. Studies of the gut microbiota (GM) have demonstrated the close link between human wellness and intestinal commensal bacteria, which mediate development of the host immune system. The dysbiosis, a disruption of...

    Authors: Jifeng Yu, Hao Sun, Weijie Cao, Lijie Han, Yongping Song, Dingming Wan and Zhongxing Jiang

    Citation: Experimental Hematology & Oncology 2020 9:35

    Content type: Review

    Published on:

  20. CD19-targeted CAR T cells therapy has shown remarkable efficacy in treatment of B cell malignancies. However, relapse of primary disease remains a major obstacle after CAR T cells therapy, and the majority of ...

    Authors: Hao Zhang, Pu Zhao and He Huang

    Citation: Experimental Hematology & Oncology 2020 9:34

    Content type: Review

    Published on:

  21. Cyclic adenosine monophosphate (cAMP) is the first discovered second messenger, which plays pivotal roles in cell signaling, and regulates many physiological and pathological processes. cAMP can regulate the t...

    Authors: Hongying Zhang, Qingbin Kong, Jiao Wang, Yangfu Jiang and Hui Hua

    Citation: Experimental Hematology & Oncology 2020 9:32

    Content type: Review

    Published on:

  22. T-cell acute lymphoblastic leukemia (T-ALL) is one of the hematological malignancies. With the applications of chemotherapy regimens and allogeneic hematopoietic stem cell transplantation, the cure rate of T-A...

    Authors: Ruyue Zheng, Menglin Li, Shujuan Wang and Yanfang Liu

    Citation: Experimental Hematology & Oncology 2020 9:31

    Content type: Review

    Published on:

  23. Outcomes of chronic myeloid leukemia (CML) has been improved dramatically in the past two decades, but survival levels of CML patients varied in regions. Comprehensive epidemiological research is necessary to ...

    Authors: Liqing Ning, Chuanyu Hu, Pingfan Lu, Yimei Que, Xiaojian Zhu and Dengju Li

    Citation: Experimental Hematology & Oncology 2020 9:29

    Content type: Research

    Published on:

  24. Pancreatic cancer is one of the most common causes of cancer-related deaths worldwide. The two major histological subtypes of pancreatic cancer are pancreatic ductal adenocarcinoma (PDAC), accounting for 90% o...

    Authors: He-Li Gao, Wen-Quan Wang, Xian-Jun Yu and Liang Liu

    Citation: Experimental Hematology & Oncology 2020 9:28

    Content type: Review

    Published on:

  25. Kidney cancer’s incidence and mortality vary in different regions and countries. To compare and interpret kidney cancer’s burden and change trends in the globe and in different countries, we conducted this stu...

    Authors: Xianguang Bai, Ming Yi, Bing Dong, Xinhua Zheng and Kongming Wu

    Citation: Experimental Hematology & Oncology 2020 9:27

    Content type: Research

    Published on:

  26. Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by constitutive activity of the tyrosine kinase BCR-ABL1. Although the introduction of tyrosine kinase inhibitors (TKIs) has substa...

    Authors: Theresa Klümper, Henrike Bruckmueller, Tobias Diewock, Meike Kaehler, Sierk Haenisch, Christiane Pott, Oliver Bruhn and Ingolf Cascorbi

    Citation: Experimental Hematology & Oncology 2020 9:26

    Content type: Research

    Published on:

  27. Novel corona virus caused pneumonia first reported in December, 2019 in Wuhan, China was later named COVID-19. Due to its special pathogenicity, COVID-19 transmitted with high speed beyond borders and has sign...

    Authors: Ehtisham Ul Haq, Jifeng Yu and Jiancheng Guo

    Citation: Experimental Hematology & Oncology 2020 9:24

    Content type: Letter to the Editor

    Published on:

  28. Pancreatic cancer continues to be one of the most aggressive malignant tumors. Work in recent years in cancer molecular biology has revealed that metabolic reprogramming is an additional hallmark of cancer tha...

    Authors: Mengqi Liu, Wensheng Liu, Yi Qin, Xiaowu Xu, Xianjun Yu, Qifeng Zhuo and Shunrong Ji

    Citation: Experimental Hematology & Oncology 2020 9:23

    Content type: Review

    Published on:

  29. Successful prevention of post-transplantation relapse after donor lymphocyte infusion (DLI) depends on its capability to mediate an effective graft-versus-leukemia (GVL) response while minimizing DLI-related t...

    Authors: Yong-Rim Kwon, Hye Joung Kim, Min-Jung Sohn, Ji-Young Lim, Kyung-Shin Park, Seok Lee, Nack-Gyun Chung, Dae-Chul Jeong, Chang-Ki Min and Yoo-Jin Kim

    Citation: Experimental Hematology & Oncology 2020 9:22

    Content type: Research

    Published on:

  30. Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined.

    Authors: José Luis Piñana, Rodrigo Martino, Irene García-García, Rocío Parody, María Dolores Morales, Gonzalo Benzo, Irene Gómez-Catalan, Rosa Coll, Ignacio De La Fuente, Alejandro Luna, Beatriz Merchán, Anabelle Chinea, Dunia de Miguel, Ana Serrano, Carmen Pérez, Carola Diaz…

    Citation: Experimental Hematology & Oncology 2020 9:21

    Content type: Research

    Published on:

  31. Despite the proven benefits of iron chelation therapy (ICT) in the management of chronic iron overload and related complications, compliance to long-term ICT is challenging. Results from the ECLIPSE study, an ...

    Authors: Immacolata Tartaglione, Raffaella Origa, Antonis Kattamis, Michael Pfeilstöcker, Sibel Gunes, Susanne Crowe, Niamh Fagan, Beatrice Vincenzi and Giovan Battista Ruffo

    Citation: Experimental Hematology & Oncology 2020 9:20

    Content type: Research

    Published on:

  32. To explore the efficacy of primary chemoradiation with cisplatin versus cetuximab with respect to HPV/p16 and smoking statuses.

    Authors: Il Seok Daniel Jeong, Huan Mo, Anthony Nguyen, Esther G. Chong, Hsin Hsiang Clarence Tsai, Justin Moyers, Matthew Kim, Curtis Lacy, Vivek Shah, Eric Lau, Yi Xu and Huynh Cao

    Citation: Experimental Hematology & Oncology 2020 9:19

    Content type: Letter to the Editor

    Published on:

  33. Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor response to chemo- and (modest-dose conventionally fractionated) radio-therapy. Emerging evidence suggests that pancreatic stellate cells (PSCs) se...

    Authors: Pei Pei Che, Alessandro Gregori, Omidreza Firuzi, Max Dahele, Peter Sminia, Godefridus J. Peters and Elisa Giovannetti

    Citation: Experimental Hematology & Oncology 2020 9:18

    Content type: Letter to the Editor

    Published on:

  34. PD-L1 expression and tumour mutational burden (TMB) are both associated with the responses of multiple tumours to immune checkpoint inhibitor (ICI) therapy. However, their prevalence and correlations may diffe...

    Authors: Yanhui Chen, Yating Wang, Hongli Luo, Xue Meng, Wei Zhu, Di Wang, Hui Zeng and Henghui Zhang

    Citation: Experimental Hematology & Oncology 2020 9:17

    Content type: Research

    Published on:

  35. Coronavirus disease 2019 (COVID-19) is a novel infectious viral disease, which lacks well-established diagnostic laboratory parameters that could be used to evaluate disease severity, thromboembolism or cardio...

    Authors: Changqian Bao, Xiandong Tao, Wei Cui, Bin Yi, Tiewen Pan, Ken H. Young and Wenbin Qian

    Citation: Experimental Hematology & Oncology 2020 9:16

    Content type: Research

    Published on:

  36. Chimeric antigen receptor (CAR) T cell therapy is a new frontier in cancer therapy. The toxicity of cytokine release syndrome (CRS) has become one of the major challenges that limits the wider use of CAR T cel...

    Authors: Zhaonian Hao, Ruyuan Li, Li Meng, Zhiqiang Han and Zhenya Hong

    Citation: Experimental Hematology & Oncology 2020 9:15

    Content type: Review

    Published on:

  37. Breast cancer is the most diagnosed malignancy in females in the United States. The members of retinal determination gene network (RDGN) including DACH, EYA, as well as SIX families participate in the prolifer...

    Authors: Bing Dong, Ming Yi, Suxia Luo, Anping Li and Kongming Wu

    Citation: Experimental Hematology & Oncology 2020 9:13

    Content type: Research

    Published on:

  38. Human prostate cancer spheres endowed with stem cell properties have been obtained from androgen-dependent cell line LNCaP after exposure to an epigenomic modulator phenethyl isothiocynate (PEITC). Sphere cell...

    Authors: Jingjing Wu, Shundong Cang, Christina Liu, Whitman Ochiai and Jen Wei Chiao

    Citation: Experimental Hematology & Oncology 2020 9:12

    Content type: Short report

    Published on:

  39. T cells expressing a chimeric antigen receptor (CAR) engineered to target CD19 can treat leukemia effectively but also increase the risk of complications such as cytokine release syndrome (CRS) and CAR T cell ...

    Authors: Liqing Kang, Xiaowen Tang, Jian Zhang, Minghao Li, Nan Xu, Wei Qi, Jingwen Tan, Xiaoyan Lou, Zhou Yu, Juanjuan Sun, Zhenkun Wang, Haiping Dai, Jia Chen, Guoqing Lin, Depei Wu and Lei Yu

    Citation: Experimental Hematology & Oncology 2020 9:11

    Content type: Research

    Published on:

  40. Immune cell infiltration in the tumor microenvironment (TME) affects tumor initiation, patients’ prognosis and immunotherapy strategies. However, their roles and interactions with genomics and molecular proces...

    Authors: Furong Liu, Lu Qin, Zhibin Liao, Jia Song, Chaoyi Yuan, Yachong Liu, Yu Wang, Heze Xu, Qiaofeng Zhang, Youliang Pei, Hongwei Zhang, Yonglong Pan, Xiaoping Chen, Zhanguo Zhang, Wanguang Zhang and Bixiang Zhang

    Citation: Experimental Hematology & Oncology 2020 9:10

    Content type: Research

    Published on:

  41. This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma c...

    Authors: Rasmus Strøm Risbjerg, Mie Vennize Hansen, Anne Sofie Sørensen and Tue Wenzel Kragstrup

    Citation: Experimental Hematology & Oncology 2020 9:9

    Content type: Letter to the Editor

    Published on:

  42. Multiple myeloma is an incurable hematological malignancy characterized by a heterogeneous genetic and epigenetic landscape. Although a number of genetic aberrations associated with myeloma pathogenesis, progr...

    Authors: Xi Yun Zhang, Deepa Rajagopalan, Tae-Hoon Chung, Lissa Hooi, Tan Boon Toh, Johann Shane Tian, Masturah Bte Mohd Abdul Rashid, Noor Rashidha Bte Meera Sahib, Mengjie Gu, Jhin Jieh Lim, Wilson Wang, Wee Joo Chng, Sudhakar Jha and Edward Kai-Hua Chow

    Citation: Experimental Hematology & Oncology 2020 9:8

    Content type: Research

    Published on:

  43. Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis or EGFR alone does not yield adequate tumor contro...

    Authors: Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, Kyaw Z. Thein, Aung Naing, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Filip Janku, Funda Meric-Bernstam, Razelle Kurzrock and Gerald Falchook

    Citation: Experimental Hematology & Oncology 2020 9:7

    Content type: Research

    Published on:

Annual Journal Metrics